Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley R Riddell

Showing results (91-100 of 177) with videos related to

Pageof 18
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 31, 2009
Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imagingZejing Wang, Rainer Storb, Donghoon Lee, et al.
The Journal of Clinical Investigation|November 2, 2016
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasiaPaulina J Paszkiewicz, Simon P Fräßle, Shivani Srivastava, et al.
Blood|March 6, 2010
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cellsMarie Bleakley, Brith E Otterud, Julia L Richardt, et al.
Blood|February 25, 2016
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyRebecca Gardner, David Wu, Sindhu Cherian, et al.
The Journal of Clinical Investigation|August 16, 2021
A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cellsJoshua R Veatch, Naina Singhi, Shivani Srivastava, et al.
Cancer Cell|March 20, 2019
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor TargetingShivani Srivastava, Alexander I Salter, Denny Liggitt, et al.
Blood|May 23, 2022
NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsivenessAlec B Wilkens, Elena C Fulton, Margot J Pont, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scaleXiuli Wang, Araceli Naranjo, Christine E Brown, et al.
Blood|October 7, 2024
Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapyDavid G Coffey, Pinar Ataca Atilla, Erden Atilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2017
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of IbrutinibCameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, et al.
Pageof 18

Showing results (91-100 of 177) with videos related to

Sort By:
Pageof 18
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 31, 2009
Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imagingZejing Wang, Rainer Storb, Donghoon Lee, et al.
The Journal of Clinical Investigation|November 2, 2016
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasiaPaulina J Paszkiewicz, Simon P Fräßle, Shivani Srivastava, et al.
Blood|March 6, 2010
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cellsMarie Bleakley, Brith E Otterud, Julia L Richardt, et al.
Blood|February 25, 2016
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapyRebecca Gardner, David Wu, Sindhu Cherian, et al.
The Journal of Clinical Investigation|August 16, 2021
A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cellsJoshua R Veatch, Naina Singhi, Shivani Srivastava, et al.
Cancer Cell|March 20, 2019
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor TargetingShivani Srivastava, Alexander I Salter, Denny Liggitt, et al.
Blood|May 23, 2022
NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsivenessAlec B Wilkens, Elena C Fulton, Margot J Pont, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scaleXiuli Wang, Araceli Naranjo, Christine E Brown, et al.
Blood|October 7, 2024
Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapyDavid G Coffey, Pinar Ataca Atilla, Erden Atilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2017
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of IbrutinibCameron J Turtle, Kevin A Hay, Laïla-Aïcha Hanafi, et al.
Pageof 18